- Home
- KALV vs TBLD Comparison
KALV vs TBLD Comparison
Compare KALV & TBLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- TBLD
- Stock Information
- Founded
- KALV N/A
- TBLD 2021
- Country
- KALV United States
- TBLD United States
- Employees
- KALV N/A
- TBLD N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- TBLD Investment Managers
- Sector
- KALV Health Care
- TBLD Finance
- Exchange
- KALV Nasdaq
- TBLD Nasdaq
- Market Cap
- KALV 637.9M
- TBLD 633.0M
- IPO Year
- KALV N/A
- TBLD N/A
- Fundamental
- Price
- KALV $12.34
- TBLD $19.77
- Analyst Decision
- KALV Strong Buy
- TBLD
- Analyst Count
- KALV 9
- TBLD 0
- Target Price
- KALV $26.29
- TBLD N/A
- AVG Volume (30 Days)
- KALV 1.0M
- TBLD 121.1K
- Earning Date
- KALV 09-04-2025
- TBLD 01-01-0001
- Dividend Yield
- KALV N/A
- TBLD 6.29%
- EPS Growth
- KALV N/A
- TBLD N/A
- EPS
- KALV N/A
- TBLD N/A
- Revenue
- KALV N/A
- TBLD N/A
- Revenue This Year
- KALV N/A
- TBLD N/A
- Revenue Next Year
- KALV $192.67
- TBLD N/A
- P/E Ratio
- KALV N/A
- TBLD N/A
- Revenue Growth
- KALV N/A
- TBLD N/A
- 52 Week Low
- KALV $7.30
- TBLD $15.80
- 52 Week High
- KALV $16.32
- TBLD $20.55
- Technical
- Relative Strength Index (RSI)
- KALV 36.00
- TBLD 54.14
- Support Level
- KALV $12.19
- TBLD $19.67
- Resistance Level
- KALV $14.35
- TBLD $20.39
- Average True Range (ATR)
- KALV 0.61
- TBLD 0.41
- MACD
- KALV -0.30
- TBLD 0.00
- Stochastic Oscillator
- KALV 5.26
- TBLD 51.85
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.